Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 954-958

  McCoy, Sara S ^a   Crowson, Cynthia S ^b   Gabriel, Sherine E ^b   Matteson, Eric L ^b  

^a Department of Health Sciences Research   (United States)

^b Mayo Clinic   (United States)

Author keywords

Cardiovascular disease; Hypothyroidism; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEVOTHYROXINE; METHOTREXATE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPOTHYROIDISM; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SUBCLINICAL HYPOTHYROIDISM; UNITED STATES;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYPOTHYROIDISM; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84860707075     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111076     Document Type: Article

References (47)

1. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum 2005;52:412-20. (Pubitemid 40216304)
2. Gabriel S. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121:S9-S14.
3. Maradit-Kremers H, Crowson C, Nicola P, Ballman K, Roger V, Jacobsen S, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005;52:402-11. (Pubitemid 40220344)
4. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11. (Pubitemid 38230289)
5. Wolfe F, Mitchell D, Sibley J, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94. (Pubitemid 24115934)
6. Silman A, Ollier W, Bubel M. Autoimmune thyroid disease and thyroid autoantibodies in rheumatoid arthritis patients and their families. Br J Rheumatol 1989;28:18-21. (Pubitemid 19107395)
7. Raterman H, van Halm V, Voskuyl A, Simsek S, Dijkmans B, Nurmohamed M. Rheumatoid arthritis is associated with a high prevalence of hypothyroid that amplifies its cardiovascular risk. Ann Rheum Dis 2008;67:229-32. (Pubitemid 351183313)
8. Chan A, Al-Saffar Z, Bucknall R. Thyroid disease in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology 2001;40:353-4. (Pubitemid 32266365)
9. Atzeni F, Doria A, Ghirardello A, Turiel M, Batticciotto A, Carrabba M, et al. Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value. Autoimmunity 2008;41:111-5.
10. Andonopoulos A, Siambi V, Makri M, Christofidou M, Markou C, Vagenakis A. Thyroid function and immune profile in rheumatoid arthritis. A controlled study. Clin Rheumatol 1996;15:599-603. (Pubitemid 26405577)
11. Melton L. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74. (Pubitemid 126784042)
12. Arnett F, Edworthy S, Bloch D, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
13. Myasoedova E, Crowson C, Kremers H, Therneau T, Gabriel S. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.
14. Ho K, Pinsky J, Kannel W, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A. (Pubitemid 23285789)
15. Mosterd A, Deckers J, Hoes A, Nederpel A, Smeets A, Linker D, et al. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol 1997;13:491-502. (Pubitemid 27306166)
16. Gooley T, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
17. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988;16:1141-54.
18. Santos M, Vinagre F, Canas da Silva J, Gil V, Fonseca J. Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of female patients. Acta Reumatol Port 2010;35:325-32.
19. Shiroky J, Cohen M, Ballachey M, Neville C. Thyroid dysfunction in rheumatoid arthritis: A controlled prospective survey. Ann Rheum Dis 1993;52:454-6. (Pubitemid 23209603)
20. Przygodzka M, Filipowicz-Sosnowska A. Prevalence of thyroid diseases and antithyroid antibodies in women with rheumatoid arthritis. Pol Arch Med Wewn 2009;119:39-43.
21. Crowson C, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011;38:29-35.
22. van Halm V, Nielen M, Nurmohamed M, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8. (Pubitemid 46226052)
23. Choi H, Hernán M, Seeger J, Robins J, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)
24. Goodson N, Symmons D, Scott D, Bunn D, Lunt M, Silman A. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-9. (Pubitemid 41117412)
25. Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6. (Pubitemid 27077826)
26. Mann D. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002;91:988-98. (Pubitemid 35416635)
27. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. (Pubitemid 27152782)
28. Ridker P, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
29. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent vasodilitation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003;88:3731-7. (Pubitemid 37034521)
30. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2006;91:5076-82. (Pubitemid 44917353)
31. Hak A, Pols H, Visser T, Drexhage H, Hofman A, Witteman J. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000;132:270-8. (Pubitemid 30106257)
32. Hazzard W, Bierman E. Aggravation of broad-disease (type 3 hyperlipoproteinemia) by hypothyroidism. Arch Intern Med 1972;130:822-8.
33. Keating FJ, Parkin T, Selby J, Dickinson L. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961;3:364-81.
34. Nikkilä E, Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1972;51:2103-14.
35. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-10. (Pubitemid 28007445)
36. Tunbridge W, Evered D, Hall R, Appleton D, Brewis M, Clark F, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clin Endocrinol 1977;7:495-508. (Pubitemid 8235966)
37. Dessein P, Norton G, Woodiwiss A, Joffe B, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007;34:943-51. (Pubitemid 46774836)
38. Berk B, Weintraub W, Alexander R. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72. (Pubitemid 20031251)
39. Biasucci L, Liuzzo G, Grillo R, Caliqiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60. (Pubitemid 29094296)
40. Rebuzzi A, Quaranta G, Liuzzo G, Caliqiuri G, Lanza GA, Gallimore JR, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998;82:715-9.
41. Downs J, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
42. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
43. Christ-Crain M, Meier C, Guglielmetti M, Huber P, Riesen W, Staub J, et al. Elevated C-reactive protein and homocysteine values: Cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003;166:379-86. (Pubitemid 36071697)
44. Hueston W, King D, Geesey M. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol 2005;63:582-7. (Pubitemid 41626755)
45. Gerdes A, Lervasi G. Thyroid replacement therapy and heart failure. Circulation 2010;122:385-93.
46. Biondi B, Fazio S, Palmieri E, Carella C, Panza N, Cittadini A, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999;84:2064-7. (Pubitemid 30647034)
47. Efstathiadoum Z, Bitsis S, Milionis H, Kukuvitis A, Bairaktari E, Elisaf M, et al. Lipid profile in subclinical hypothyroidism: Is L-thyroxine substitution beneficial? Eur J Endocrinol 2001;145:605-710.